Results 81 to 90 of about 2,428,275 (198)
Фактори експериментальної еволюції організмів, 2014 Aims. Three forms of fusion protein BCR/ABL differ by the presence or absence of PH and DH domains of BCR protein and cause different phenotypes of myeloproliferative disorders.
Д. С. Гур’янов +4 more
doaj
Tumor Biology, 2017 Imatinib mesylate, a BCR/ABL fusion protein inhibitor, is the first-line treatment against chronic myelogenous leukemia. In spite of its advantageous viewpoints, imatinib still has genuine impediments like undesirable side effects and tumor resistance ...
Alphy Rose James +9 more
doaj +1 more source
Pharmacology Research &Perspectives, Volume 14, Issue 4, August 2026.ABSTRACT Interindividual variability (IIV) in drug response complicates both fixed‐dose design and individualized therapy. Understanding how pharmacokinetic (PK) and pharmacodynamic (PD) processes jointly shape this variability is essential, particularly in combination therapy, where multiple interacting pathways influence outcomes. This study employed
Kuteesa R. Bisaso +3 more
wiley +1 more source
Cells, 2019 Leukemias bearing mixed lineage leukemia (MLL) rearrangement (MLL-R) resulting in expression of oncogenic MLL fusion proteins (MLL-FPs) represent an especially aggressive disease subtype with the worst overall prognoses and chemotherapeutic response. MLL-
Aditya Barve +7 more
doaj +1 more source
Di-san junyi daxue xuebao, 2021 Objective To investigate the laboratory and clinical characteristics of acute lymphoblastic leukemia (ALL) with e1a3 BCR-ABL fusion protein. Methods The clinical data, and results of bone marrow cytology, flow cytometry, karyotyping, fluorescence in situ hybridization (FISH) and real-time fluorescence quantitative PCR of 2 ALL cases with e1a3 BCR-ABL ...
CHEN Siyu +6 more
openaire +1 more source
Chemistry – A European Journal, Volume 32, Issue 26, 11 July 2026.Conformational restriction strategies to increase the activity and selectivity of the STAT5b inhibitor Stafib‐2 are presented. The best conformationally restricted inhibitor Stafib‐2‐CR has threefold higher activity against STAT5b than Stafib‐2. A cell‐permeable prodrug of Stafib‐2‐CR inhibits phosphorylation of STAT5b in cultured human leukemia cells ...
Theresa Münzel +5 more
wiley +1 more source
Untersuchungen zur Regulierung und Funktion der Mitogen-aktivierten Proteinkinase ERK5 = Regulation and Function of the Mitogen-activated Protein Kinase ERK5 [PDF]
, 2003 Mitogen activated protein kinases (MAPKs) are found in all eukaryotic cells and represent crucial elements in the signal transduction from the plasma membrane to the nucleus.
Buschbeck, Marcus
core
Revista Brasileira de Hematologia e Hemoterapia, 2010 A eosinofilia é freqüente na prática clínica, principalmente quando os valores estão entre 500 e 1000 eosinófilos/uL e indica a presença de doença parasitária, alérgica ou reação a medicamentos.
Maria de Lourdes Lopes Ferrari Chauffaille
doaj +1 more source
Detection of BCR-ABL kinase domain mutations in CD34+ cells from newly diagnosed chronic phase CML patients and their association with imatinib resistance [PDF]
, 2011 BCR-ABL kinase domain (KD) mutations, the most common cause of imatinib resistance, are infrequently detected in newly diagnosed chronic-phase chronic myeloid leukemia (CP-CML) patients.
Riaz ul-Haq +19 more
core
Haematologica, 2003 BACKGROUND AND OBJECTIVES: The p210 bcr-abl fusion protein has a key role in the pathogenesis of chronic myeloid leukemia (CML). However, its influence on disease progression to blast crisis is marginal and mostly due to its effect of impairing the ...
G Brusa +9 more
doaj